Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility
Primary result · Postprandial FGF19 (AUC0-240 min)Result — go to the resultTreatment ratio 0.52 95% CI 0.39–0.69Authors' conclusion
Compared with placebo, treatment with liraglutide decreased postprandial FGF19 and GLP-2 concentrations and increased postprandial CCK concentrations, which may explain the delayed postprandial gallbladder refilling observed in individuals with obesity treated with liraglutide.
Study context
- Population
- Participants with obesity; 50% male, age 47.6 ± 10.0 years, BMI 32.6 ± 3.4 kg/m² (mean ± SD)randomized 1:1
- Participants
- 52 participants
- Comparison
- Liraglutide vs placebo
Methodological detailsdouble-blind, placebo-controlled, 12-week
- Double-blind
- Placebo-controlled
- 12-week
Primary result
Postprandial FGF19 (AUC0-240 min) · after the first dose
Treatment ratio
0.52
95% CI 0.39–0.69
By group
Liraglutidevs Placebo
treatment ratio 0.52 (95% CI 0.39–0.69)
As reported in the abstract
Further findings
| Outcome | Liraglutide | Placebo | Treatment ratio (CI) | |
|---|---|---|---|---|
| Postprandial FGF19 (AUC0-240 min) · 12 weeks | 33.7 ng/ml × min | 48.5 ng/ml × min | 0.69 (0.52–0.93) | |
| Postprandial GLP-2 (AUC0-240 min) · after the first dose | 3650 min × pmol/L | 4894 min × pmol/L | 0.75 (0.62–0.90) | |
| Postprandial GLP-2 (AUC0-240 min) · 12 weeks | 3760 min × pmol/L | 4882 min × pmol/L | 0.77 (0.60–0.99) | |
| Postprandial CCK (AUC0-240 min) · after the first dose | 762 min × pmol/L | 670 min × pmol/L | 1.14 (0.97–1.33) | |
| Postprandial CCK (AUC0-240 min) · 12 weeks | 873 min × pmol/L | 628 min × pmol/L | 1.39 (1.12–1.73) | |
| 0.512Treatment ratio (log scale) |
Original publication
Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility. Diabetes Obes Metab. Published 13 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →